Background Monoclonal gammopathy of undetermined signifi cance (MGUS) is defi ned by expression of heavy-chain immunoglobulin (IgH) and is the precursor lesion for 80% of cases of multiple myeloma. The remaining 20% are characterised by absence of IgH expression; we aimed to assess prevalence of a corresponding precursor entity, lightchain MGUS.
Introduction
Monoclonal gammopathy of undetermined signifi cance (MGUS) is a precursor lesion for multiple myeloma, which is an incurable malignant disease aff ecting bone marrow that has a yearly incidence of roughly 4·6 per 100 000 population. 1 Historically, MGUS has been characterised by evidence of immunoglobulin heavychain (IgH) expression, but could therefore account for only 80% of cases of multiple myeloma, since in the remaining 20% no IgH (eg, IgG, IgA, IgD, or IgE) is secreted. 2 The prevalence and risk of progression of the premalignant precursor entity for light-chain multiple myeloma is unknown.
We postulated that an equivalent of MGUS in which IgH is not expressed-ie, light-chain MGUS-is the premalignant precursor of light-chain multiple myeloma. We previously used a serum agarose gel electrophoretic screening method to show that the prevalence of standard heavy-chain-associated MGUS was 3·2% in the population aged 50 years or older in Olmsted County, MN, USA (a predominantly white population), but identifi ed only two patients in 21 463 people tested who had free light-chain expression in serum without heavy-chain expression. 2 We postulated that the serum immunoglobulin free lightchain assay, 3 which can detect imbalances of unbound κ and λ light chains when circulating concentrations are as low as 10-30 mg/L, 4-7 might provide us with better sensitivity than would protein electrophoresis to detect this putative entity of light-chain MGUS. Clonality is defi ned as a ratio of κ to λ that is outside the reference range. This defi nition depends on the ratio, rather than the absolute concentration of either chain independently, because both renal disease and polyclonal activation of B cells can cause a diff use increase of both κ and λ plasma cells, yielding raised absolute concentrations of free κ and λ chains, but maintaining a normal ratio. We aimed to use the free light-chain assay to estimate prevalence of light-chain MGUS in the large, well defi ned, Olmsted County cohort that was originally assembled to estimate prevalence and progression of plasma-cell disorders. 2 We also described progression of this novel disorder to myeloma or related malignant disease.
Methods

Patients
We used a population-based cohort that we had previously assembled to estimate prevalence of MGUS. 2 The original cohort consisted of 21 463 of the 28 038 enumerated Olmsted County residents aged 50 years or older on Jan 1, 1995 who had serum samples available. Written informed consent for the previous study included permission for further tests and studies on the samples, and for this study we did a serum immunoglobulin free-light-chain assay on all samples with suffi cient remaining serum.
Procedures
After approval by the Mayo Clinic institutional review board, we applied the free light-chain assay (FREELITE, The Binding Site Ltd, Birmingham, UK) to stored serum samples using a Dade Behring BNII automated nephelometer (Siemens, Newark, DE, USA). The assay reports free κ and λ light-chain concentrations and the κ to λ ratio. 8 We defi ned an abnormal result as a ratio outside the normal diagnostic range (0·26-1·65). The serum protein electrophoresis assay and serum immunofi xation electrophoresis were done as previously reported. 9 The limit of detection for these assays in our laboratory was 10 mg/L. Light-chain MGUS was defi ned as an abnormal free light-chain ratio with no IgH expression, plus an increase in concentration of the involved light chain.
Statistical analysis
Although serum samples were obtained during several years, 2 each participant was assessed only once. We calculated age-specifi c and sex-specifi c prevalence rates using number of patients with light-chain MGUS in each age and sex stratum as the numerator and number of people tested in the corresponding age and sex stratum as the denominator. Age-adjusted and overall age-adjusted and sex-adjusted prevalence rates were obtained by direct standardisation to the US population aged 50 years and older in 2000. 95% CIs for prevalence rates were calculated with the assumption of a Poisson distribution. We checked Poisson models for overdispersion (a form of goodness of fi t). The age-specifi c prevalence pattern was examined as a smoothed function of age, separately by sex, with the use of generalised additive model procedures for Poisson regression. 10 The number of people with an abnormal free light-chain ratio, MGUS, or light-chain MGUS was entered as the dependent variable, age as the independent variable, and the number of people with samples tested as an off set. This method has been used previously to study prevalence of hip fractures. 11 Samples for which identifying data had been masked were necessarily omitted from calculation of progression.
We calculated progression rates using a person-years approach, in which number of recorded progressions was divided by total person-years of exposure. Rates were expressed as number of progression events per 100 personyears. Risk of progression was also analysed in the context of our previous MGUS risk model, in which we showed that patients with intact immunoglobulin MGUS and an abnormal free light-chain ratio had a higher risk of progression than did patients with a normal ratio (hazard ratio 3·5, 95% CI 2·3-5·5; p<0·0001). 12 We depicted progression rates graphically using Kaplan-Meier curves. We checked Cox models for goodness of fi t with respect to outliers and proportional hazards using the methods of Therneau and Gronbach. 13 We also assessed incidence of renal disorders in patients with light-chain MGUS by crossreferencing free-light-chain MGUS data with patients in our disease-association study, which used the Hospital Adaptation of the International Classifi cation of Diseases (8th edn) to assign diagnoses.
14 All analyses were done with SAS (version 8.2) and Splus (version 8.0).
Role of the funding source
The Binding Site, UK, which provided reagents for this study, had no role in study design, collection, analysis, and interpretation of data, writing of the report, or the decision to submit for publication. AB, director of The Binding Site, participated in critical review of the report. AD and her Mayo Clinic colleagues had full access to all data in the study and had fi nal responsibility for the decision to submit for publication. Neither The Binding Site nor AB participated in this decision. κ and λ concentrations relative to the normal range are delineated in the webappendix p 1 for the 397 people with abnormal free light-chain ratios and no IgH expression. 146 (37%) of these individuals had an increase in concentration of the light chain that was the cause of the abnormal ratio and met criteria for light-chain MGUS. The overall prevalence of light-chain MGUS was 0·8% (95% CI 0·7-0·9; table 2). Figure 1 shows the prevalence of an abnormal free light-chain ratio without increased absolute concentrations of either κ or λ.
Results
Suffi
Demographic characteristics of participants are shown in the webappendix p 2. The median age of patients with light-chain MGUS was 68 (range 50·0-96·0) years, compared with 70 (50·0-96·0) years for those with conventional MGUS. 108 people with lightchain MGUS had κ and 38 had λ predominance (2·8:1). The monoclonal free light chain could be detected with serum immunofi xation electrophoresis for only 26 (18%) of the 146 individuals with light-chain MGUS (nine κ and 17 λ). Two of these patients had been identifi ed by protein electrophoresis in the original survey, 2 but were not included in the intact immunoglobulin MGUS group. For two additional patients with light-chain MGUS, a discrepancy between immunofi xation electrophoresis and free light-chain ratio results was noted, representing either assay error or biclonality. The median concentration of involved free light chain in patients with light-chain MGUS who had positive immunofi xation electrophoresis results was signifi cantly higher than in patients with lightchain MGUS who had normal immunofi xation electrophoresis results (176 mg/L vs 48 mg/L, p<0·0001).
59 samples for which identifying data had been masked were necessarily omitted from calculation of progression, leaving 133 patients with light-chain MGUS and 577 with conventional MGUS. At 155 540 patient-years of followup for the entire cohort, progression to multiple myeloma or other disease had occurred in 62 patients (fi gure 2, table 3). Only three of the 133 unmasked cases of light-chain MGUS have progressed to multiple myeloma during 1100 patient-years of follow-up (table 4) . These three progressions, which occurred at 19, 23, and 98 months, were all to light-chain multiple myeloma. The rate of progression from light-chain MGUS to any lymphoproliferative disorder was higher than the rate of progression in patients with normal free light-chain ratios (p<0·0001), suggesting that light-chain MGUS is a premalignant plasma-cell disorder that is analogous to MGUS (table 3) .
We next compared risk of progression for light-chain MGUS with that of conventional MGUS, which has an overall progression rate of 1·0 (0·73-1·33) per 100 person-years. 2 A coexisting abnormal free lightchain ratio increased risk of progression within the conventional MGUS cohort, but risk of progression did See Online for webappendix not diff er between patients with low-risk conventional MGUS (ie, no coexisting abnormal ratio) and those with light-chain MGUS (p=0·1822). Thus, either the rates were similar or the power to detect a diff erence was restricted by the small sample size. Finally, we assessed overall survival of all groups to correct for missed progression events (eg, undiagnosed amyloidosis) that could have contributed to early mortality. Overall survival mirrored progression events (data not shown).
Renal disease raises serum concentrations of both κ and λ free light chains and in view of changes in catabolism of light chains during renal failure a socalled renal reference range has been proposed for use in interpretation of free light-chain ratios in patients with renal insuffi ciency. 16 When the renal reference range rather than the normal range was applied to the entire cohort, 69 individuals with apparent κ restriction were no longer deemed to have light-chain MGUS, but 57 people with apparent λ restriction were added (fi gure 3; webappendix p 3), including one patient who developed IgG λ multiple myeloma 90 months after acquisition of her research specimen. Because full medical information was not available for all patients, we did not use the renal reference range to calculate prevalence data. However, we noted an association between light-chain MGUS and renal diagnoses. By merging the present dataset with that from our report on MGUS disease association, 14 we showed that in the 16 255 patients in both datasets, risk of a renal diagnosis was increased in patients with MGUS or light-chain MGUS ( MGUS had some form of renal diagnosis that was not recognised as being related to a plasma-cell dyscrasia either at the time of acquisition of the test sample or subsequently. 18 (60%) of 2707 patients who had renal disease had λ-restricted light-chain MGUS.
Discussion
The term MGUS was coined more than 30 years ago at the Mayo Clinic in reference to asymptomatic individuals with an intact serum monoclonal protein concentration (both immunoglobulin heavy-chain and light-chain detectable) lower than 30 g/L and with less than 10% plasma cells in bone marrow. 2, 17, 18 MGUS was shown to be the precursor lesion for intact immunoglobulin multiple myeloma. 19 Roughly 80% of patients with multiple myeloma have IgH expression (ie, IgG, IgA, IgM, IgD, and IgE); no IgH is expressed in the remaining 20%. Before our original description of lightchain MGUS, 20 a premalignant lesion for light-chain multiple myeloma corresponding to MGUS had not been systematically described. However, a disorder called idiopathic Bence-Jones proteinuria was defi ned in seven patients who had urinary excretion of monoclonal protein of at least 1 g in 24 h without evidence of multiple myeloma or related disorders. 21 In view of our present work, these patients could be considered the fi rst cases of light-chain MGUS, but prevalence was not addressed. We have shown that 19% of cases of MGUS are of light-chain type, which is consistent with the proportion of light-chain only cases among newly diagnosed cases of multiple myeloma, 22 and our estimate that 0·8% of the general population aged 50 years and older have light-chain MGUS.
Recognition and description of this entity is important for two reasons. First, it provides insight into an additional precursor lesion for multiple myeloma, which is a devastating malignant disease. Second, the natural history of light-chain MGUS needs to be understood to promote appropriate testing for patients with this fairly benign disorder. Patients with light-chain MGUS had a progression rate of only 0·3% per year-which was lower than that of their counterparts with conventional MGUS, who had an overall yearly risk of progression of 1·0%-but 23% of this group have or will develop renal disease. The low progression rate was perhaps unexpected in the context of our previous fi nding that patients who have intact immunoglobulin MGUS, but who also have an abnormal free light-chain ratio, are at higher risk of progression than are their counterparts with a normal ratio. 12 We have shown, however, that progression rates of patients with low-risk conventional MGUS (ie, without coexisting abnormal free light-chain ratios) and those with light-chain MGUS were similar.
Whether these diff erential risks of progression are a function of tumour burden, biology, or a combination of the two is unknown. The transforming events producing light-chain and conventional heavy-chain MGUS (with a normal free light-chain ratio) could conceivably be the same, whereas conventional MGUS combined with an abnormal ratio might be a manifestation of an additional eff ect that is one step closer to full transformation to active multiple myeloma. 23 Light-chain MGUS might be detected earlier than is conventional MGUS (ie, at a point of earlier tumour burden) since the serum free lightchain ratio (which can detect involved free light-chain concentrations lower than 10-30 mg/L) is more sensitive than serum protein electrophoresis screening (1-2 g/L). 3, 8 In this study, we detected an additional 57 patients with previously unrecognised MGUS by use of the free lightchain assay, increasing the prevalence of conventional MGUS in this population from 3·2% 2 to 3·4% and defi ning the prevalence of MGUS overall as 4·2%. A fi nal explanation could be that a small proportion of our lightchain MGUS cohort-ie, patients with the least abnormal ratios-do not have a true clonal disorder, but rather renal dysfunction or polyclonal activation.
Our description of light-chain MGUS is substantiated by three recent reports. Landgren and colleagues, 24 in collaboration with our group, showed that either conventional or light-chain MGUS is present in more than 96% of patients with multiple myeloma more than 6 years before diagnosis of malignant disease. If lightchain MGUS were excluded, only 93% of patients with multiple myeloma had premalignant MGUS before diagnosis. Thus, in a small subset of patients with multiple myeloma the precursor lesion is not MGUS, but rather light-chain MGUS. Results of a second similar study 25 showed that light-chain MGUS was the preceding premalignant lesion for light-chain multiple myeloma. These results substantiate our previous report that heavychain MGUS progresses only to multiple myeloma with heavy-chain immunoglobulin expression. Taken together, they lend strong support to our fi ndings. Finally, in a slightly diff erent vein, Tsai and co-workers 26 showed that in 109 patients with chronic lymphocytic leukaemia, prevalence of an abnormal free light-chain ratio before diagnosis was 38% (95% CI 29-47); none of the patients with light-chain MGUS in our cohort has yet developed chronic lymphocytic leukaemia.
For the purposes of disease defi nition, we excluded from the light-chain MGUS category those individuals with an abnormal free light-chain ratio who had no increase in the involved light chain. This group, constituting 63% of all individuals with an abnormal ratio and no IgH expression, might include a subset of patients with true light-chain MGUS, but were regarded as false positives for two reasons. First, since an abnormal ratio in the context of B-cell disorders is used as a surrogate for clonality, abnormality in the ratio caused by only relative suppression of the other immunoglobulin free light chain seems insuffi cient evidence for a clone. Second, when we explored the prevalence of abnormal ratios with neither raised κ nor λ concentrations, the age distribution was the inverse of that seen in MGUS.
A more specifi c defi nition of light-chain MGUS could include only the subset of patients who were immunofi xation positive (26 of 146 cases), but such a defi nition would have missed all three patients with lightchain MGUS who progressed to multiple myeloma in this series. Since the free light-chain ratio is more sensitive for detection of free light chains than is serum immunofi xation, [4] [5] [6] [7] 9 reliance on immunofi xation alone would also greatly underestimate the true prevalence of light-chain MGUS. Our trust in the free light-chain assay to detect clonal disorders in the setting of negative immunofi xation is lent support by Weiss and colleagues. 25 Their series included 30 patients with multiple myeloma for whom prediagnostic serum (taken 2·2 to 15·3 years before diagnosis) was available for retrospective testing for monoclonal gammopathy. In six of these patients, the fi rst evidence of a plasma-cell clone was the free lightchain ratio alone, and two subsequently had an IgH detected by immunofi xation before diagnosis of nonlight-chain multiple myeloma.
Another more specifi c defi nition of light-chain MGUS might use the renal reference range. 16 This exercise increased the number of λ cases by 57 and decreased the number of κ cases by 69, which did not substantially change the prevalence rate, but did aff ect the population at risk. Because the defi nition of renal range does not take into account degrees of renal dysfunction, 16 we could not select patients to whom the renal reference range should have been applied. Use of the normal reference range rather than the renal range, albeit imperfect, allowed for the greatest consistency in the setting of this large population study. Another confounder of our prevalence estimates is that recognition of MGUS-be it conventional or light-chain type-depends on the screening method used. As the sensitivity of screening technology increases, the prevalence of an entity also seems to increase. For conventional MGUS, detection rates have risen with increasing sensitivity of the screening method from paper electrophoresis 17 to agarose gel electrophoresis 2 to free light-chain measurements.
An important limitation of this study is the absence of African American participants in the Olmsted County cohort. Conventional MGUS is two to three times more common in the African American population than it is in white people, and our population study does not provide information about the prevalence of light-chain MGUS in this group. 27 We also noted an association with renal disease that needs further study. We do not recommend screening for this disorder; however, we expect patients to be identifi ed incidentally when a free light-chain assay is ordered as part of a diagnostic assessment for various symptoms and laboratory abnormalities such as anaemia, hypercalcaemia, or renal failure. If light-chain MGUS is identifi ed in the context of one of these abnormalities, as with conventional MGUS we recommend that a diagnosis of multiple myeloma, amyloidosis, and related disorders is excluded by use of a bone marrow examination and clonality testing, imaging studies, renal biopsy, and Congo red staining of fat or other tissue as clinically appropriate. If no malignant disorder is recognised, the free light-chain assay should be repeated in 6 months and yearly thereafter; no therapy is needed as long as there is no progression. Our data suggest that periodic monitoring of renal function is prudent, since 23% of these patients either have or will develop renal disease. Patients with light-chain MGUS are at risk of light-chain multiple myeloma, amyloidosis, and renal disorders and hence will need further assessment if symptoms suggesting these disorders are encountered during follow-up. We postulate that light-chain MGUS occurs as a consequence of translocations involving the immunoglobulin heavy-chain region at chromosome 14q32, which results in total suppression of heavy-chain production.
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